Edwards Lifesciences Severance accrual, current decreased by 1.3% to $23.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.0%, from $22.00M to $23.10M. Over 5 years (FY 2020 to FY 2025), Severance accrual, current shows an upward trend with a 10.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests active cost-cutting or organizational transformation, while a decrease indicates the completion of restructuring phases.
This represents the portion of estimated costs associated with restructuring activities, such as employee severance, tha...
Commonly seen during periods of industry consolidation or strategic pivots; varies significantly by company cycle.
other_restructuring_reserve_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.80M | $20.40M | $19.10M | $19.40M | $13.20M | $16.20M | $15.60M | $14.80M | $14.40M | $13.80M | $12.30M | $10.20M | $8.90M | $39.60M | $27.40M | $22.00M | $19.90M | $19.60M | $23.40M | $23.10M |
| QoQ Change | — | +14.6% | -6.4% | +1.6% | -32.0% | +22.7% | -3.7% | -5.1% | -2.7% | -4.2% | -10.9% | -17.1% | -12.7% | +344.9% | -30.8% | -19.7% | -9.5% | -1.5% | +19.4% | -1.3% |
| YoY Change | — | — | — | — | -25.8% | -20.6% | -18.3% | -23.7% | +9.1% | -14.8% | -21.2% | -31.1% | -38.2% | +187.0% | +122.8% | +115.7% | +123.6% | -50.5% | -14.6% | +5.0% |